Iradimed (IRMD) Income towards Parent Company (2013 - 2026)

Iradimed (IRMD) has reported Income towards Parent Company for 14 consecutive years, with $5.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Income towards Parent Company fell 9.63% year-over-year to $5.2 million in Q2 2026; TTM through Jun 2026 was $23.0 million, a 15.13% increase from a year earlier, with the FY2025 full-year figure at $22.4 million, up 20.87% from the prior year.
• Income towards Parent Company was $5.2 million for Q2 2026 at Iradimed, down from $5.8 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at $6.4 million in Q4 2025 and troughed at $2.5 million in Q1 2022.
• A 5-year average of $4.5 million and a median of $4.6 million in 2024 frame the typical range for Income towards Parent Company.
• Across the five-year window, Income towards Parent Company surged 120.53% in 2022 and slipped 15.13% in 2023, its largest moves.
• Over 5 years, Income towards Parent Company stood at $3.7 million in 2022, then dropped by 15.13% to $3.1 million in 2023, then surged by 42.69% to $4.4 million in 2024, then soared by 43.12% to $6.4 million in 2025, then slipped by 18.05% to $5.2 million in 2026.
• The last three Income towards Parent Company figures came in at $5.2 million (Q2 2026), $5.8 million (Q1 2026), and $6.4 million (Q4 2025), per Business Quant data.